Skye Bioscience
SKYE · Nasdaq · United States
Share price · SKYE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SKYE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 12 Nov 2026+17.5%
- 10 Nov 2026+21.6%
Nothing announced by SKYE that day or the session before.
- 9 Nov 2026-30.3%
Nothing announced by SKYE that day or the session before.
- 16 Sep 2026-19.4%
Nothing announced by SKYE that day or the session before.
- 9 Sep 2026+18.6%
Nothing announced by SKYE that day or the session before.
- 19 Aug 2026-14.8%
- 18 Aug 2026-13.5%
Nothing announced by SKYE that day or the session before.
- 17 Aug 2026-17.2%
- 6 Aug 2026-16.0%
Nothing announced by SKYE that day or the session before.
- 22 May 2026+15.9%
Nothing announced by SKYE that day or the session before.
Share of unusual movement by asset
For each asset, the share of SKYE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
nimacimabevents and moves
| 4 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 13% |
| Other company news (earnings, financing, releases naming no asset) | — | 11% |
| Sessions with no dated event | — | 76% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | CB1 receptorMonoclonal antibody | Obesity |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $1.3M | $4.8M+ $0 short-term inv. | —-$5.1M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $3.9M | $8.1M+ $2.0M short-term inv. | $11M-$7.1M operating cash flow | report ↗ |
| 2026-Q1 | — | $7.9M | $8.2M+ $9.0M short-term inv. | $13M-$8.6M operating cash flow | report ↗ |
| 2025-Q3 | — | $9.4M | $18M+ $17M short-term inv. | $13M-$13M operating cash flow | report ↗ |
| 2025-Q2 | — | $14M | $24M+ $25M short-term inv. | $18M-$11M operating cash flow | report ↗ |
| 2025-Q1 | — | $7.2M | $46M+ $13M short-term inv. | $11M-$9.2M operating cash flow | report ↗ |
| 2024-Q3 | — | $4.9M | $76M | $3.9M-$5.3M operating cash flow | report ↗ |
| 2024-Q2 | — | $4.1M | $83M | $7.9M-$7.1M operating cash flow | report ↗ |
| 2024-Q1 | — | $1.9M | $92M | $5.0M-$4.7M operating cash flow | report ↗ |
| 2023-Q3 | — | $1.3M | $14M | $25M-$4.0M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.8M | $0.6M | $3.1M-$2.0M operating cash flow | report ↗ |
| 2023-Q1 | — | $1.2M | $2.7M | $5.2M-$4.1M operating cash flow | report ↗ |
| 2022-Q3 | — | $1.8M | $0.4M | $3.1M-$2.1M operating cash flow | report ↗ |
| 2022-Q2 | — | — | $2.9M | $3.4M-$2.9M operating cash flow | report ↗ |
| 2022-Q1 | — | — | $6.0M | $3.0M-$2.9M operating cash flow | report ↗ |
| 2021-Q3 | — | — | $11M | $1.8M-$1.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $42M | $5.9M+ $20M short-term inv. | $14M-$43M operating cash flow | report ↗ |
Skye Bioscience reported no revenue for fiscal year 2025. R&D spend was $42.36M, up 126.5% YoY from $18.7M. Cash and equivalents totaled $5.88M, with a net loss of $55.92M and a quarterly net burn of $55.92M.
During the year, the company advanced nimacimab; the CBeyond Phase 2a trial showed the 200 mg monotherapy did not meet its primary endpoint, while the combination with semaglutide achieved -13.2% versus -10.25% weight loss (p=0.0372) with a favorable safety profile. Interim extension data showed 52-week mean weight loss of 22.3% in the combination arm. The company initiated a Phase 2a expansion study (Part C) evaluating intravenous nimacimab, with topline data expected in the fourth quarter of 2026, and full extension topline data expected in the third quarter of 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $19M | $68M+ $0 short-term inv. | $6.6M-$25M operating cash flow | report ↗ |
| 2023-FY | — | $5.8M | $10M | $9.4M-$14M operating cash flow | report ↗ |
| 2022-FY | — | $6.0M | $1.3M | $4.9M-$13M operating cash flow | report ↗ |
| 2021-FY | — | — | $9.0M | $2.1M-$6.5M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 30 sales ($889K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-23 | 5AM Partners VII, LLC; 5AM Ventures VII, L.P.; 5AM Partners II, LLC; 5AM Ventures II LP; 5AM CO-INVESTORS II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner | Open-market sale | 114,851 | $1.61 | $185K | Form 4 |
| 2026-09-23 | Schwab Andrew J. · director, 10% owner | Open-market sale | 114,851 | $1.61 | $185K | Form 4 |
| 2026-09-23 | 5AM Partners VII, LLC; 5AM Ventures VII, L.P.; 5AM Partners II, LLC; 5AM Ventures II LP; 5AM CO-INVESTORS II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner | Open-market sale | 4,528 | $1.61 | $7K | Form 4 |
| 2026-09-23 | Schwab Andrew J. · director, 10% owner | Open-market sale | 4,528 | $1.61 | $7K | Form 4 |
| 2026-09-22 | 5AM Partners VII, LLC; 5AM Ventures VII, L.P.; 5AM Partners II, LLC; 5AM Ventures II LP; 5AM CO-INVESTORS II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner | Open-market sale | 27,612 | $1.65 | $46K | Form 4 |
| 2026-09-22 | Schwab Andrew J. · director, 10% owner | Open-market sale | 27,612 | $1.65 | $46K | Form 4 |
| 2026-09-22 | 5AM Partners VII, LLC; 5AM Ventures VII, L.P.; 5AM Partners II, LLC; 5AM Ventures II LP; 5AM CO-INVESTORS II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner | Open-market sale | 1,088 | $1.65 | $2K | Form 4 |
| 2026-09-22 | Schwab Andrew J. · director, 10% owner | Open-market sale | 1,088 | $1.65 | $2K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 39 reporting institutions held 16.1M shares ($9.9M, 45.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | 5AM Venture Management, LLC | 9,681,763 | $6.0M |
| 2 | Versant Venture Management, LLC | 2,007,704 | $1.2M |
| 3 | BAKER BROS. ADVISORS LP | 1,575,243 | $968K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 764,457 | $470K |
| 5 | SPHERA FUNDS MANAGEMENT LTD. | 678,928 | $417K |
| 6 | BlackRock, Inc. | 286,131 | $176K |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 277,256 | $170K |
| 8 | MILLENNIUM MANAGEMENT LLC | 258,200 | $159K |
| 9 | PLATINUM INVESTMENT MANAGEMENT LTD | 233,095 | $143K |
| 10 | VANGUARD FIDUCIARY TRUST CO | 104,229 | $64K |
| 11 | STATE STREET CORP | 75,326 | $46K |
| 12 | UBS Group AG | 45,762 | $28K |
| 13 | XTX Topco Ltd | 40,919 | $25K |
| 14 | TWO SIGMA INVESTMENTS, LP | 25,684 | $16K |
| 15 | Engineers Gate Manager LP | 20,194 | $12K |